Merck UK Expansion Cancelled – No State Investment

Here’s a summary of the key points from the provided text:

MSD is reducing its UK presence: The ‍pharmaceutical company MSD is ending operations at⁤ its UK manufacturing site by⁢ the end of the year, resulting in 125 job losses.
Reasons cited: Lack of ‍UK investment & undervaluation of medicines: MSD blames a lack of investment in the UK life science industry and the undervaluation of innovative medicines and vaccines⁤ by the‍ UK government.
Broader Industry Trend: This isn’t an isolated incident. ⁤AstraZeneca also pulled a £450m investment earlier this year, and other companies‍ are‍ signaling similar concerns. Novartis has already been unable⁢ to launch several medicines in the UK.
NHS Spending on Pharmaceuticals‍ is Down: ⁤Experts point to a decline in the percentage of healthcare spending allocated to pharmaceuticals in the UK (down from 15% to 9% over 10⁢ years), compared to the‍ OECD average of 14-20%. Companies need ⁢to be able to sell their ‍products.
UK Competitiveness is Key: Industry ⁤leaders⁤ emphasize the UK’s declining competitiveness as the primary driver of these decisions. They highlight systematic under-investment in⁤ innovative products.
Not Just About‍ Drug Pricing (Though it’s ⁢a factor): While drug pricing negotiations ‍are ongoing,sources suggest the⁢ issue is broader than just price – it’s about the overall investment⁣ climate. The current pricing regime was agreed to less ⁣than 18 months ago.
Positive Area -⁣ Kings Cross Hub: The UK has* been attracting funding in the area ⁣of life sciences and AI around⁣ Kings Cross, but this isn’t enough to offset the ⁤broader issues.

In essence, the article‍ paints a picture of a pharmaceutical⁤ industry losing confidence‍ in the UK as a viable place to invest and operate, due to a combination of government policy, NHS spending priorities, ⁤and overall market competitiveness.